Billion Firm Perplexity Says Fear of Copycats Drives Success
Perplexity's CEO argues that embracing the risk of idea theft keeps a fast-moving AI startup on its toes. The comment...
Compare fund families based on index fund history and identify which has demonstrated the strongest long-term performance and stability.
28,115 articlesPerplexity's CEO argues that embracing the risk of idea theft keeps a fast-moving AI startup on its toes. The comment...
A biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
A once-sacrosanct pledge to never dump bitcoin treasury holdings is showing cracks as firms explore selling slices to...
The latest CBO budget update shows the Treasury's interest costs rising to nearly $3 billion per day as debt nears $3...
Strategy unveiled a plan to repurchase roughly $1.5 billion of its 2029 notes, with funding options including Bitcoin...
Berkshire Hathaway is positioned to become a much larger Alphabet holder as the tech giant pursues a bold AI financin...
A record biotech IPO backdrop has investors buzzing about Parabilis Medicines. This guide breaks down what the surge ...
Retirees are increasingly aiming for dependable cash flow without depleting principal. A $850,000 portfolio that quie...
Physician burnout and shifting market conditions are prompting some doctors with $1.6 million in 401(K) savings to pu...
Entrepreneurship powered America’s rise, and Steve Case argues we must expand that engine nationwide to guard the cou...
Investors often chase big biotech gains, but Viking Therapeutics stock really hinges on milestones and cash runway. T...
As the AI memory crunch enters its second year, three ETFs map different angles of the supply squeeze—from DRAM to br...